Compare Abeona Therapeutics Inc (ABEO) vs Vanguard Ultra Short Bond ETF (VUSB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Vanguard Ultra Short Bond ETF — how do they compare? Abeona Therapeutics Inc trades at $6.71 (market cap $373.32M), while Vanguard Ultra Short Bond ETF trades at $49.63. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, Vanguard Ultra Short Bond ETF nearer its low. Which is the better fit depends on your goals.
| ABEO | VUSB | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $7.23 | $50.03 |
52-Week Low | $4.17 | $49.60 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
VUSB trades at $49.66, up 0.04% with a bearish technical signal from moving averages. The ETF offers a yield around 4.35% and recent dividends of $0.17-$0.18, positioning it as a cash alternative amid potential Fed rate changes. Financial ratios are unavailable, but sentiment highlights its role in short-term bond strategies.
Outlook hinges on interest rate trends, with opportunities in yield advantage over money markets. Risks include credit and duration exposure. Analyst coverage is limited for this ETF, requiring investor due diligence on underlying holdings and macroeconomic shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Vanguard Ultra Short Bond ETF
VUSB is an actively managed ETF from Vanguard that invests in a diversified portfolio of high-quality, investment-grade fixed income securities with maturities typically under two years. It is designed to offer higher yield potential than traditional money market funds while maintaining limited price volatility, making it a strategic tool for managing short-term reserves with a 6-to-18-month horizon.
Read more on VUSB →
